Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (NERV): 1 pipeline candidate · 2 upcoming catalysts · ~42 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
42.1 months
D/E -1.35 · 0% dilution
Lead: Phase 3
1 candidate
2 upcoming, next in ~897d
N/A
A transparent, data-derived signal for Minerva Neurosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$201.0M
Cash
$32.8M
Quarterly Burn
$5.4M
Runway
42.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| roluperidone | Phase 3 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
39
Total value held
$190.4M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 8,588,518 | $51.7M |
| federated hermes, inc. | 5,113,224 | $30.8M |
| balyasny asset management l.p. | 4,258,600 | $25.7M |
| vanguard capital management llc | 3,691,662 | $22.2M |
| farallon capital management llc | 2,365,000 | $14.2M |
| adage capital partners gp, l.l.c. | 1,419,000 | $8.5M |
| trails edge capital partners, lp | 1,419,000 | $8.5M |
| dv trading llc | 889,254 | $5.4M |
| acuta capital partners, llc | 709,500 | $4.3M |
| millennium management llc | 708,291 | $4.3M |
Showing top 10 of 39 institutional holders of Minerva Neurosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Minerva Neurosciences, Inc.'s pipeline?
Minerva Neurosciences, Inc. (NERV) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Minerva Neurosciences, Inc.'s lead drug candidate?
Minerva Neurosciences, Inc.'s most advanced tracked candidate is roluperidone (Phase 3) for Negative Symptoms of Schizophrenia.
What is Minerva Neurosciences, Inc.'s next catalyst?
Minerva Neurosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate " — expected December 1, 2028.
What is Minerva Neurosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Minerva Neurosciences, Inc. has approximately 42.1 months of cash runway.
What is Minerva Neurosciences, Inc.'s market capitalization?
Minerva Neurosciences, Inc.'s market capitalization is approximately $201.0M.
Get the full picture on Minerva Neurosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.